Literature DB >> 8359163

Immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharides and exotoxin A in patients with cystic fibrosis or bacteremia.

A Brauner1, S J Cryz, M Granström, H S Hanson, L Löfstrand, B Strandvik, B Wretlind.   

Abstract

IgG antibodies to nine Pseudomonas aeruginosa lipopolysaccharides (LPS) and exotoxin A in sera from 11 patients with bacteremia and 51 patients with cystic fibrosis (CF) were analyzed. The methods used were enzyme immunoassay (EIA) and immunoblotting. Nine of the 11 bacteremic patients were infected with strains expressing an LPS serotype identical to one of the test antigens. In sera from six of these nine patients, antibody homologous to the serotype of the infecting strain was observed. An antibody response to heterologous Pseudomonas aeruginosa LPS antigens was observed in nine patients. Eight of the bacteremic patients mounted an antibody response to exotoxin A. Thirty-five CF patients chronically colonized with Pseudomonas aeruginosa possessed significantly higher levels of antibody to all of the test antigens than 16 patients with intermittent or no colonization (p < 0.001). For exotoxin A and serotype 3 the sensitivity was 91% and 94%, and the specificity 94% and 88% respectively. When the results for exotoxin A and serotype 3 were combined, the sensitivity was 91% while the specificity was 81%. The pronounced antibody response to heterologous LPS antigens, as measured by the EIA and immunoblot, suggests expression of a common antigen determinant. A simplified serological assay utilizing exotoxin A and serotype 3 as test antigens may be useful for detecting Pseudomonas aeruginosa infections in patients with CF and chronic colonization and in bacteremic patients from whom cultures are not available.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8359163     DOI: 10.1007/bf01967437

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  27 in total

1.  The specificity of agglutination reactions of Pseudomonas aeruginosa with O antisera.

Authors:  T L Pitt; Y J Erdman
Journal:  J Med Microbiol       Date:  1978-02       Impact factor: 2.472

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Progressive increase in antibiotic resistance of gram-negative bacterial isolates. Walter Reed Hospital, 1976 to 1980: specific analysis of gentamicin, tobramycin, and amikacin resistance.

Authors:  A S Cross; S Opal; D J Kopecko
Journal:  Arch Intern Med       Date:  1983-11

4.  Diagnosis of chronic Pseudomonas aeruginosa infection in cystic fibrosis by enzyme-linked immunosorbent assay.

Authors:  S S Pedersen; F Espersen; N Høiby
Journal:  J Clin Microbiol       Date:  1987-10       Impact factor: 5.948

5.  Antilipopolysaccharide antibodies and differential diagnosis of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.

Authors:  A Fomsgaard; B Dinesen; G H Shand; T Pressler; N Høiby
Journal:  J Clin Microbiol       Date:  1989-06       Impact factor: 5.948

6.  Antibody response of fibrocystic patients to homologous 0-typable and 0-defective isolates of Pseudomonas aeruginosa.

Authors:  J MacDougall; M E Hodson; T L Pitt
Journal:  J Clin Pathol       Date:  1990-07       Impact factor: 3.411

7.  Occurrence of P-fimbriated Escherichia coli in patients with bacteremia.

Authors:  A Brauner; M Leissner; B Wretlind; I Julander; S B Svenson; G Källenius
Journal:  Eur J Clin Microbiol       Date:  1985-12       Impact factor: 3.267

8.  Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man.

Authors:  M Pollack; L S Young
Journal:  J Clin Invest       Date:  1979-02       Impact factor: 14.808

9.  Heterogeneity of lipopolysaccharides from Pseudomonas aeruginosa: analysis of lipopolysaccharide chain length.

Authors:  M Rivera; L E Bryan; R E Hancock; E J McGroarty
Journal:  J Bacteriol       Date:  1988-02       Impact factor: 3.490

10.  Prospective study of serum antibodies to Pseudomonas aeruginosa exoproteins in cystic fibrosis.

Authors:  A E Hollsing; M Granström; M L Vasil; B Wretlind; B Strandvik
Journal:  J Clin Microbiol       Date:  1987-10       Impact factor: 11.677

View more
  7 in total

1.  Anti-Pseudomonas aeruginosa antibody detection in patients with bronchiectasis without cystic fibrosis.

Authors:  E Caballero; M E Drobnic; M T Pérez; J M Manresa; A Ferrer; R Orriols
Journal:  Thorax       Date:  2001-09       Impact factor: 9.139

2.  Amount and Avidity of IgG Antibodies to Pseudomonas Aeruginosa Exotoxin A Antigen in Cystic Fibrosis Patients.

Authors:  Janja Polanec; Jan Patzer; Jacek Grzybowski; Milan Strukelj; Zlatko P Pavelic
Journal:  Pathol Oncol Res       Date:  1997       Impact factor: 3.201

3.  The Pseudomonas aeruginosa PA01 gene collection.

Authors:  Joshua Labaer; Qingqing Qiu; Anukanth Anumanthan; Wenhong Mar; Dongmei Zuo; T V S Murthy; Helen Taycher; Allison Halleck; Eugenie Hainsworth; Stephen Lory; Leonardo Brizuela
Journal:  Genome Res       Date:  2004-10       Impact factor: 9.043

4.  IL-23 mediates inflammatory responses to mucoid Pseudomonas aeruginosa lung infection in mice.

Authors:  Patricia J Dubin; Jay K Kolls
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2006-10-27       Impact factor: 5.464

5.  lfnA from Pseudomonas aeruginosa O12 and wbuX from Escherichia coli O145 encode membrane-associated proteins and are required for expression of 2,6-dideoxy-2-acetamidino-L-galactose in lipopolysaccharide O antigen.

Authors:  Jerry D King; Erin F Mulrooney; Evgeny Vinogradov; Bernd Kneidinger; Kristen Mead; Joseph S Lam
Journal:  J Bacteriol       Date:  2007-12-21       Impact factor: 3.490

6.  Sera from adult patients with cystic fibrosis contain antibodies to Pseudomonas aeruginosa type III apparatus.

Authors:  J Moss; M E Ehrmantraut; B D Banwart; D W Frank; J T Barbieri
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

7.  Inhibition of bacterial motility with human antiflagellar monoclonal antibodies attenuates Pseudomonas aeruginosa-induced pneumonia in the immunocompetent rat.

Authors:  W J Landsperger; K D Kelly-Wintenberg; T C Montie; L S Knight; M B Hansen; C C Huntenburg; M J Schneidkraut
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.